| The clinical utility of teledermoscopy in the era of telemedicine SK Uppal, J Beer, E Hadeler, H Gitlow, K Nouri Dermatologic therapy 34 (2), e14766, 2021 | 38 | 2021 |
| Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis SK Uppal, DG Kearns, VS Chat, G Han, JJ Wu Journal of Dermatological Treatment 33 (2), 626-636, 2022 | 25 | 2022 |
| Use of systemic therapies for psoriasis in the COVID-19 era DG Kearns, S Uppal, VS Chat, JJ Wu Journal of Dermatological Treatment 33 (2), 622-625, 2022 | 19 | 2022 |
| Clinical management of psoriasis patients during the COVID-19 pandemic VS Chat, SK Uppal, DG Kearns, JJ Wu Journal of Dermatological Treatment 33 (2), 1166-1167, 2022 | 17 | 2022 |
| Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic DG Kearns, S Uppal, VS Chat, JJ Wu Journal of the American Academy of Dermatology 83 (3), e251, 2020 | 17 | 2020 |
| Management of psoriasis with topicals: Applying the 2020 AAD-NPF guidelines of care to clinical practice VS Chat, DG Kearns, SK Uppal, G Han, JJ Wu Cutis 110 (2 Suppl), 8-14, 2022 | 14 | 2022 |
| Comparison of guidelines for the use of interleukin-17 inhibitors for psoriasis in the United States, Britain, and Europe: a critical appraisal and comprehensive review DG Kearns, S Uppal, VS Chat, JJ Wu The Journal of Clinical and Aesthetic Dermatology 14 (6), 55, 2021 | 13 | 2021 |
| Applying to dermatology residency during the COVID-19 pandemic DG Kearns, VS Chat, S Uppal, JJ Wu Journal of the American Academy of Dermatology 83 (4), 1214-1215, 2020 | 11 | 2020 |
| Ruxolitinib cream for the treatment of vitiligo SK Uppal, DG Kearns, VS Chat, JJ Wu The Lancet 396 (10264), 1735-1736, 2020 | 7 | 2020 |
| Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis. SK Uppal, VS Chat, DG Kearns, JJ Wu Journal of Drugs in Dermatology: JDD 19 (10), 956-959, 2020 | 7 | 2020 |
| Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: a critical appraisal and comprehensive review VS Chat, SK Uppal, DG Kearns, JJ Wu Dermatologic Therapy 34 (4), e14974, 2021 | 5 | 2021 |
| Assessing the risk of apremilast use for psoriasis during the COVID-19 pandemic DG Kearns, S Uppal, VS Chat, JJ Wu Journal of drugs in dermatology: JDD 20 (5), 582-583, 2021 | 5 | 2021 |
| Translating the 2020 AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologics to clinical practice VS Chat, SK Uppal, DG Kearns, G Han, JJ Wu Cutis 107 (2), 99-103, 2021 | 5 | 2021 |
| Translating the 2019 AAD-NPF guidelines of care for the management of psoriasis with phototherapy DG Kearns, S Uppal, VS Chat, G Han, JJ Wu Cutis 106 (2), 82-86, 2020 | 4 | 2020 |
| Translating the 2019 AAD-NPF guidelines of care for psoriasis with attention to comorbidities VS Chat, SK Uppal, DG Kearns, G Han, JJ Wu Cutis 108 (2S), 7-11, 2021 | 3 | 2021 |
| Abrocitinib for atopic dermatitis SK Uppal, VS Chat, DG Kearns, JJ Wu The Lancet 397 (10270), 195-196, 2021 | 3 | 2021 |
| Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic DG Kearns, VS Chat, S Uppal, JJ Wu Journal of the American Academy of Dermatology 83 (6), e433-e434, 2020 | 3 | 2020 |
| Dermatologists as social media contributors during the COVID-19 pandemic. SK Uppal, DG Kearns, VS Chat, JJ Wu Cutis 106 (5), 2020 | 2 | 2020 |
| Phase 2 and 3 trials of JAK inhibitors for atopic dermatitis: a review DG Kearns, SK Uppal, VS Chat, JJ Wu Practical Dermatol, 50-54, 2020 | 2 | 2020 |
| Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy VS Chat, DG Kearns, SK Uppal, JJ Wu Journal of Dermatological Treatment 32 (5), 495-496, 2021 | 1 | 2021 |